Whole Exome Sequencing Cost and Self-Pay Testing Options

What whole exome sequencing includes

Whole exome sequencing, often shortened to WES or exome sequencing, is a genetic test that reads the protein-coding portions of thousands of genes. These coding regions are called exons. They make up a small percentage of the genome, but they contain many of the currently known disease-causing variants that clinical genetics teams can interpret. MedlinePlus Genetics explains that whole exome sequencing focuses on the exome, while whole genome sequencing reads a much broader portion of a person’s DNA.

In a medical setting, WES is not just “getting your DNA file.” A clinical exome usually includes sample processing, DNA sequencing, bioinformatics analysis, variant classification, clinical interpretation, and a signed laboratory report. The lab typically analyzes the person being tested, called the proband, in the context of the medical reason for testing: developmental delay, seizures, congenital anomalies, unexplained neurologic findings, suspected metabolic disease, recurrent fetal anomalies, or another concern that suggests a genetic condition.

Many orders are placed as a trio exome, meaning the lab sequences the proband and two biological parents. Trio testing can clarify whether a variant was inherited from a parent or occurred de novo, meaning newly in the child. This can shorten the interpretation process and may reduce the number of uncertain findings. Some labs also offer duo testing, quad testing, rapid exome sequencing, prenatal exome sequencing, reanalysis of old exome data, or reflex testing from exome to genome.

Professional guidelines increasingly support exome or genome sequencing in specific pediatric scenarios. The American College of Medical Genetics and Genomics guideline for children with congenital anomalies, developmental delay, or intellectual disability strongly recommends considering exome or genome sequencing as a first- or second-tier test for those indications. That does not mean WES is the right test for every person, but it explains why many specialists now discuss exome earlier in the diagnostic process instead of only after years of single-gene and panel testing.

How much does whole exome sequencing cost?

For a self-pay consumer in the United States, a realistic whole exome sequencing cost can fall into several different ranges:

• About $900–$1,500: lower published cash prices for proband-only clinical exome, before separate clinician or counseling fees.
• About $2,000–$3,500: common self-pay territory for trio exome, research-adjacent exome in a CLIA lab, or clinical exome plus ordering and counseling support.
• About $5,000–$8,000+: rapid exome, quad testing, certain hospital-based listed prices, or complex prenatal or institutional workflows.
• Insurance-billed amounts: may be much higher than cash prices and are not the same as what a self-pay patient would owe after a written estimate or financial assistance.

Published examples illustrate the spread. Revvity lists a self-pay price of $900 for proband-only whole exome sequencing and $2,700 for trio whole exome sequencing. The same lab lists $5,650 for rapid quad whole exome sequencing, reflecting the added family members and faster turnaround. Johns Hopkins’ clinical exome page lists $7,100 for exome trio, showing how hospital-based list pricing can be substantially different from a commercial lab cash price.

The best way to compare prices is to calculate the effective cost to the patient. For example, a $900 proband-only lab price may become $1,150 if you also need a $250 pre-test telehealth genetics visit to order the test. If you want a separate post-test counseling session, the effective cost may increase again. Conversely, a higher lab price may include services that another lab charges separately. Always ask what is included before comparing two numbers.

Self-pay testing options: clinical, hospital, telehealth, and research-oriented

1. Clinical lab WES ordered by your own clinician

This is often the cleanest route when you already have a geneticist, neurologist, developmental pediatrician, maternal-fetal medicine specialist, or other clinician who is comfortable ordering exome sequencing. The clinician chooses a lab, documents the indication, signs the requisition, coordinates samples, and receives the report. If you self-pay, the lab may require payment before testing begins.

The advantage is that the test is integrated into your medical care. Your clinician can match the exome to your symptoms, decide whether parents or other relatives should be tested, and interpret the result alongside imaging, physical exam findings, metabolic labs, or prior genetic tests. The disadvantage is access: genetics clinics may have long waits, and some primary care offices are understandably hesitant to order a complex genomic test without genetics support.

2. Telehealth genetic counseling plus a clinical lab

If you do not have a local genetics appointment, a telehealth genetics visit may help determine whether WES is appropriate and, if so, which lab and test configuration make sense. Genome Medical states that genetic counseling visits are done by phone and typically last 30–60 minutes, and that a visit costs up to $250 depending on insurance or self-pay status; genetic testing itself is not included in that counseling fee. GeneDx’s patient billing page also notes a Genome Medical self-pay pathway of $250 for pre-test counseling, order placement, and results summary, with an additional $250 for post-test counseling if desired. See Genome Medical’s individual genetics service page and GeneDx’s billing information.

This path can be practical for self-pay users because it separates the ordering support from the lab bill. However, it is still medical care, not a shopping cart purchase. State licensure, age, indication, sample requirements, and clinical appropriateness may affect whether the service can order a particular test for you.

3. Hospital-based exome sequencing

Academic medical centers and children’s hospitals may offer exome sequencing through their own molecular diagnostics lab or a send-out program. Hospital pricing may look high on a public charge list, but the patient’s actual out-of-pocket cost depends on insurance contracts, financial assistance, prior authorization, and whether the hospital uses institutional billing. This route may be valuable for complex cases because the genetics team, specialists, and laboratory may communicate closely. It may be less attractive for straightforward self-pay comparison because listed charges can be much higher than commercial self-pay prices.

4. Research-oriented exome programs

Some programs offer exome sequencing through research or data-sharing initiatives. For example, MyGene2 describes a self-pay route for families not selected for University of Washington Center for Mendelian Genomics sequencing, with $725 per sample or $2,095 for a trio for CLIA-certified whole exome sequencing, plus an extra processing fee for credit card payment. This may be attractive for families with suspected Mendelian disease who are comfortable with the program’s research and data-sharing model. It is not the same as ordering a conventional diagnostic exome through your treating clinician, so read the consent, reporting, privacy, and follow-up details carefully.

5. Consumer genome products

Low-cost consumer genome or exome-like products may appeal to people who want raw data. They are not always equivalent to a clinical diagnostic WES report. Consumer tests may differ in coverage, confirmation, variant interpretation, reporting scope, medical oversight, privacy terms, reanalysis, and whether a healthcare system will accept the result for diagnosis. If you are trying to explain a medical problem, ask whether the result will be generated by a CLIA-certified clinical laboratory, whether a licensed clinician will receive the report, and whether pathogenic or likely pathogenic findings will be confirmed and classified under accepted clinical standards.

Whole exome sequencing cost comparison

The table below compares publicly available consumer-facing information. Prices can change, and some major clinical labs do not publish a single cash price because the final amount depends on test type, billing method, insurance, patient assistance, and ordering channel. Do not treat “contact lab” as a negative; it means you need a written estimate before authorizing testing.

What affects the price of whole exome sequencing?

Proband-only vs trio vs quad

A proband-only exome sequences one person. A trio sequences the proband and two biological parents. A quad typically adds another relative, often a sibling or another parent in a specific family structure. More samples cost more, but they can improve interpretation. Trio testing is especially valuable when the person being tested is a child and the suspected condition could be caused by a de novo variant, recessive inheritance, X-linked inheritance, or an inherited variant with variable symptoms in a parent.

Standard vs rapid turnaround

Routine WES often takes about four to eight weeks after the lab receives all samples and paperwork. Rapid exome may be used for seriously ill infants, NICU/PICU cases, urgent prenatal decisions, or time-sensitive clinical situations. Rapid testing costs more because the lab prioritizes the case, compresses interpretation, and may require additional staffing or workflow changes. If the result is not medically urgent, standard turnaround is usually more cost-effective.

Clinical interpretation depth

Two tests can both be called “exome” but differ in what is analyzed and reported. Ask whether the lab includes mitochondrial DNA, copy-number variant analysis from exome data, selected deep intronic variants, pharmacogenetic findings, secondary findings, or phenotype-driven reanalysis. A cheaper test that provides raw data only is not equivalent to a diagnostic exome report signed out by a clinical laboratory director.

Secondary findings

Clinical exome and genome testing may offer analysis for medically actionable secondary findings: variants unrelated to the reason for testing but associated with conditions where screening or prevention may help. The ACMG maintains a secondary findings list for clinical exome and genome sequencing; its policy statements are available through the ACMG policy statement page. Before testing, ask whether secondary findings are included, optional, or billed separately, and whether minors are handled differently from adults.

Reanalysis

A negative or uncertain exome today may become more informative later as gene-disease relationships improve. Some labs include one reanalysis within a specified period; others charge separately. Variantyx, for example, states in its provider FAQ that it offers one reanalysis of original sequencing data within three years for certain comprehensive analyses, including Genomic Unity exome and genome analyses. See the Variantyx provider FAQ. When comparing prices, reanalysis can be a meaningful benefit.

Insurance workflow

If you bill insurance first, your eventual bill may depend on authorization, denial, deductible, coinsurance, appeal, and whether the lab lets you switch to a cash-pay rate. Some self-pay prices cannot be submitted to insurance or counted toward your deductible. Variantyx explicitly notes that if you choose self-pay pricing, the amount paid does not contribute to your annual deductible and cannot be submitted as an insurance claim. That type of rule can make a lower cash price less attractive if you are close to meeting your deductible.

Genetic counseling and medical follow-up

Pre-test counseling helps clarify whether exome is the right test, whether parents should be included, what secondary findings mean, and what a negative or uncertain result can and cannot rule out. Post-test counseling can be equally important, particularly if the report includes a pathogenic variant, likely pathogenic variant, variant of uncertain significance, unexpected family relationship finding, or secondary finding. Counseling fees may be included in some workflows and separate in others.

What results can you get from WES?

Most clinical WES reports fall into a few broad categories:

• Positive: The lab identifies a pathogenic or likely pathogenic variant that explains the clinical question.
• Negative or nondiagnostic: No reportable variant is found that explains the symptoms. This does not rule out a genetic condition.
• Variant of uncertain significance: A genetic change is found, but current evidence is not enough to classify it as disease-causing or benign.
• Secondary finding: A medically actionable variant unrelated to the original reason for testing may be reported if that analysis was selected and applicable.
• Carrier finding: Some labs may report carrier status for recessive conditions, depending on the test policy and indication.

Diagnostic yield varies by patient group, test design, and whether family members are included. A 2025 meta-analysis of genome and exome sequencing in pediatric rare and undiagnosed genetic diseases reported a pooled diagnostic yield of 34.2% for genome-wide sequencing compared with 18.1% for non-genome-wide testing in within-cohort studies. See the PubMed abstract for the 2025 Genetics in Medicine meta-analysis. A positive result can sometimes change management, end a diagnostic search, guide surveillance, clarify recurrence risk, or identify relatives who may benefit from testing. A negative result may still be useful if it prevents repeated low-yield testing, but it can also be frustrating because WES cannot detect every genetic cause.

Limitations that matter before you pay

Whole exome sequencing is broad, but it is not complete. It may miss variants in noncoding regions, repeat expansions, balanced structural rearrangements, methylation disorders, low-level mosaicism, some copy-number changes, mitochondrial heteroplasmy below a lab’s threshold, or variants in poorly covered exons. Some genes are technically difficult to sequence because of pseudogenes, high GC content, or repetitive regions. If the suspected condition is known to involve repeat expansions, methylation, chromosomal rearrangements, or a specific difficult gene, a targeted test may be better than WES.

WES is also only as good as the clinical information provided. A detailed phenotype, family history, physical findings, imaging, prior genetic results, and relevant lab values can help the laboratory prioritize variants. When the requisition says only “rule out genetic disease,” interpretation is harder. If possible, ask your clinician to include Human Phenotype Ontology terms, major diagnoses, age of onset, negative findings, and prior testing.

Finally, WES can reveal information that affects relatives. A result may show that a parent is a carrier, that a parent has a mild or unrecognized form of the condition, or that reported biological relationships do not match the genetic data. These possibilities should be discussed before testing, especially in trio testing.

Questions to ask before paying for whole exome sequencing

If you are comparing two or three labs, create a simple spreadsheet with the exact test name, test code, listed cash price, required visit fees, included relatives, turnaround, reanalysis policy, and whether your clinician is comfortable using that lab. A lower price is not automatically better if the test lacks the analysis needed for your medical question, but a higher price is not automatically better either.

When WES may be worth considering

Whole exome sequencing is most useful when the medical question is broad and many genes could plausibly explain the symptoms. Common examples include developmental delay or intellectual disability, multiple congenital anomalies, unexplained seizures, suspected rare neurologic disease, unexplained muscle disease, complex syndromic features, and some fetal anomalies after standard chromosome testing is nondiagnostic. It may also be considered after a negative targeted panel when the suspicion for a genetic condition remains high.

WES may be less useful when the clinical question is narrow and a cheaper targeted test is available. For example, if a known familial variant needs to be checked, single-site testing is usually more appropriate. If the concern is a common pharmacogenetic question, a pharmacogenetic panel may be more practical. If the suspected diagnosis involves a repeat expansion, methylation defect, or chromosome-level change, a different test may be needed. A genetics professional can help match the test to the question before you spend thousands of dollars.

FAQs about whole exome sequencing cost

How much does whole exome sequencing cost without insurance?

Without insurance, WES can cost under $1,000 for some proband-only clinical self-pay options and several thousand dollars for trio, rapid, prenatal, or hospital-based testing. The effective total may also include an ordering visit, genetic counseling, blood draw, shipping, and follow-up.

Is trio exome more expensive than proband-only exome?

Yes. Trio exome usually costs more because it includes the patient and two biological parents. The extra cost can be worthwhile when parental data are important for interpretation, particularly in pediatric rare disease and developmental conditions.

Can I order WES without a doctor?

Most clinical WES requires a licensed clinician order. If you do not have a local genetics clinician, telehealth genetic counseling may be an option. Consumer DNA products may be easier to buy directly, but they are not a substitute for a clinically ordered diagnostic exome when a medical diagnosis is the goal.

Will insurance cover whole exome sequencing?

It depends on your plan and indication. Coverage is more likely when the test is medically necessary, supported by professional guidelines, ordered by an appropriate clinician, and documented with relevant history and prior testing. Preauthorization is common. Always request a written estimate and ask what happens if the claim is denied.

Why do some labs not publish a WES cash price?

Some labs price exome sequencing based on the exact test, family structure, billing method, insurance status, institutional contract, financial assistance eligibility, and whether the order is rapid, prenatal, or part of a broader genome-wide assay. If a price is not posted, call billing and ask for a good faith estimate for the exact test code.

Is whole genome sequencing a better deal than whole exome sequencing?

Sometimes, but not always. Whole genome sequencing reads more of the genome and may detect some variant types that exome can miss. However, insurance coverage, interpretation, reporting, and clinical usefulness depend on the indication. A cheaper consumer WGS product may still be less useful than a clinical WES ordered for a specific medical question.

What is reanalysis, and should I pay for it?

Reanalysis means the lab reviews existing exome data again as medical knowledge improves or the patient’s symptoms change. It can be valuable after a negative or uncertain result. Before paying for WES, ask whether one reanalysis is included, when it can be requested, and what future reanalysis costs.

Does WES test for all genetic diseases?

No. WES focuses mainly on coding regions and may miss repeat expansions, methylation disorders, many noncoding variants, balanced rearrangements, some copy-number variants, and regions with poor coverage. A negative WES result does not rule out every genetic condition.

Are public customer reviews useful when choosing a WES lab?

They can reveal billing and communication themes, but they are a weak measure of laboratory quality. Clinical genetics labs are better compared by test scope, accreditation, ordering workflow, report quality, turnaround time, reanalysis policy, clinician familiarity, and written cost transparency. Billing complaints are common across medical testing because insurance estimates, denials, and deductibles can be confusing.

What is the smartest next step if I am paying cash?

Get the exact test name and code from the ordering clinician, request a written self-pay estimate from the lab, ask whether counseling and reanalysis are included, and compare the effective total cost rather than the headline lab price alone.

Bottom line

The headline whole exome sequencing cost can be misleading. A $900 proband-only clinical exome, a $2,700 trio exome, and a $7,100 hospital trio exome may all be legitimate options, but they are not identical products or workflows. The right comparison is the total cost to the patient for the exact clinical question: who is tested, what is analyzed, who orders it, who explains the result, how quickly it is needed, and whether reanalysis is included.

If you are self-paying, do not authorize testing based on a verbal ballpark alone. Ask for a written estimate, confirm whether insurance will be involved, and make sure the result will be clinically usable for the decision you are trying to make. Whole exome sequencing can be a powerful diagnostic tool, but it is most valuable when the test, the patient’s symptoms, and the interpretation plan are aligned before the sample is collected.